KRIBIOLISA™ Blinatumomab ELISA (BLINCYTO™)
ELISA for the detection of Blinatumomab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year
Receive your quote directly from the manufacturer.
Blinatumomab, sold under the brand name Blincyto, is used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. A bispecific antibody (specifically, a bi-specific T cell engager antibody), it transiently link CD19-expressing target cells with cytotoxic T cells by bridging to the CD3e subunit of the T-cell receptor. Blinatumomab recruits T-cells to CD19+ target cells thus activating T cells for further proliferation, cytokine production and granzyme B release. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-HodgkinUs Lymphoma including in patients who are refractory to chemotherapy.
